CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union December 13, 2024
DanCann Pharma A/S Recommends Experienced Politician and Senior Government Official to Join the Board of Directors November 25, 2024
